• MSD Korea’s sales rise 69% in 2 years
• by Jung, Sae-Im Apr 17, 2023 05:58am

• Policy
• Kyowa Kirin accepted the evaluation results for Nephoxil
• by Lee, Tak-Sun Apr 17, 2023 05:58am

• Company
• Will the leukemia ADC Mylotarg be reimb this time?
• by Eo, Yun-Ho Apr 17, 2023 05:58am

• Company
• Sales of cepha antibiotics make a rebound
• by Kim, Jin-Gu Apr 14, 2023 05:49am

• Policy
• Obesity treatment Mounjaro, soon to launch in Korea
• by Lee, Hye-Kyung Apr 14, 2023 05:49am

• Policy
• SGLT2+DPP4 combinations are to be released next month
• by Lee, Tak-Sun Apr 14, 2023 05:49am

• Company
• “Reimb standard for hemophilia should align with approvals"
• by Jung, Sae-Im Apr 14, 2023 05:49am

• Company
• “Olumiant rises as a new option for alopecia areata”
• by Jung, Sae-Im Apr 13, 2023 05:46am

• Company
• SK Bioscience “Booster SKYCovione demonstrates effect"
• by Kim, Jin-Gu Apr 13, 2023 05:46am

• Policy
• Domestic approval of Pemazyre is imminent
• by Lee, Hye-Kyung Apr 13, 2023 05:45am